Dark History of Clinical Trials Part 6

In this episode, we dive into a chilling case where a promising T-cell therapy showed remarkable results in adolescents and pediatric patients — but when tested in adults, the outcome was tragically different. Phase 1 looked fine, Phase 2 turned deadly. To this day, we still don’t fully understand why. Was it biology? Trial design? Or something deeper about the risks of pushing boundaries in science? Join us as we unpack what went wrong, and what this story teaches us about the fragile line between breakthrough and disaster in clinical research.